綠葉製藥(02186.HK)附屬批出歐洲四國明多日透皮貼劑獨家商業化權利
綠葉製藥(02186.HK)公布,全資附屬公司綠葉瑞士與Italfarmaco訂立協議。
據此,Italfarmaco獲得新藥利斯的明多日透皮貼劑在歐洲四個國家的獨家商業化權利。
Italfarmaco獲得在德國、意大利、葡萄牙和希臘商業化利斯的明多天貼劑的獨家權利。Italfarmaco也將擁有在智利和越南商業化利斯的明多天貼劑的優先權利。Italfarmaco將在該協定簽署後向集團支付首付款,並在達成若干銷售里程碑時,支付額外的付款。集團也將獲得來自Italfarmaco的特許權使用費。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.